Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > 01093 CSPC PHARMA > Key Indicators
01093 CSPC PHARMA
7.000
-0.110-1.55%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30
Per Share IndicaTor
Operating Cash Flow Per Share
51.54% 0.4172 -- -- -29.04% 0.4746 -- --
Cash Flow Per Share
-6513.5% -0.216 -- -- -40.77% 0.1845 -- --
Operating Income Per Share
10.26% 1.5296 22.28% 0.8136 15.24% 2.8522 -29.18% 2.0694
Net Asset Per Share
11.74% 2.7478 -- -- 20.02% 2.6598 -- --
Basic Earning Per Share
-5.47% 0.291 -0.03% 0.1454 11.84% 0.5735 29.96% 0.4353
Diluted  Earning Per Share
-5.47% 0.291 -0.03% 0.1454 11.84% 0.5735 30% 0.4353
Profitability
Gross Profit Ratio
-4.61% 72.636% -4.14% 73.800% 1.24% 75.843% 0.81% 75.844%
Operating Profit Ratio
-9.23% 23.884% -15.92% 22.358% 0.42% 24.384% 16.3% 25.108%
Net Profit Ratio
-13.79% 19.392% -18.1% 18.216% -2.64% 20.412% 14.49% 21.302%
Earning Before Tax Ratio
-10.08% 23.827% -15.45% 22.402% -4.11% 24.571% 9.13% 25.298%
ROE
-18.31% 10.743% -- -- -9.6% 23.511% -- --
ROA
-19.38% 7.891% -- -- -6.92% 17.529% -- --
Yield Quality
Operating Profit To Total Profits
0.95% 100.239% -0.56% 99.804% 4.72% 99.238% 6.57% 99.251%
Tax To Total Profits
23.13% 18.615% 16.4% 18.687% -6.91% 16.926% -19.97% 15.796%
Operating Cash To Total Revenue
37.44% 27.272% -- -- -38.42% 16.638% -- --
Capital Structure
Debt Assets Ratio
5.62% 24.263% -- -- -1.72% 22.778% -- --
Equity Multipler
3.29% 1.385 -- -- -0.71% 1.3369 -- --
Debt Equity Ratio
7.41% 32.036% -- -- -2.23% 29.496% -- --
Current Assets To tatal Assets
1.01% 58.778% -- -- 10.56% 58.537% -- --
Non Current Assets To Total Assets
-1.4% 41.222% -- -- -11.88% 41.463% -- --
Current Liabilities To tatal Liabilities
-2.13% 89.769% -- -- 0.98% 91.315% -- --
Non Current Liabilities To Total Liabilities
23.65% 10.231% -- -- -9.29% 8.685% -- --
Solvency
Current Ratio
-2.28% 2.6986 -- -- 11.39% 2.8143 -- --
Quick Ratio
-4.36% 2.3884 -- -- 10.75% 2.4711 -- --
Operating Profit To Current Liabilities
-16.11% 0.4407 -- -- -2.16% 0.9403 -- --
Operrating Cash Flow To Current Liabilities
27.02% 0.5033 -- -- -40% 0.6417 -- --
Share Equity Without Minority Interest To Total Liabilities
-8.34% 2.9757 -- -- 2.48% 3.2839 -- --
Operating Cash Flow To Total Liabilities
24.31% 0.4518 -- -- -39.41% 0.5859 -- --
Operating Profit To Total Liabilities
-17.9% 0.3957 -- -- -1.2% 0.8587 -- --
Operating Capacity
Inventory Turnover(T)
-8.9% 1.637 -- -- 6.47% 3.1396 -- --
Current Assets Turnover(T)
-10.73% 0.7079 -- -- -10.16% 1.5567 -- --
Fixed Assets Turnover(T)
0.36% 1.7607 -- -- 9.23% 3.4665 -- --
Total Assets Turnover(T)
-5.99% 0.4153 -- -- -4.27% 0.8715 -- --
Growth Ability
Operating Revenue GR 3Y
-19.16% 43.645% 7.78% 51.606% -32.27% 62.081% -40.76% 56.341%
Gross Income GR 3Y
-41.01% 49.283% -22.23% 59.995% -37.62% 85.801% -45.72% 82.010%
Operating Profit GR 3Y
-27.52% 63.898% -29.4% 61.053% -22.06% 83.150% -0.56% 81.105%
EBT GR 3Y
-29.66% 63.670% -28.83% 61.164% -27.78% 86.036% -13.28% 83.816%
Net Profit GR 3Y
-36.93% 64.897% -36.21% 60.165% -25.71% 91.729% -4.14% 94.212%
Net Profit Attributable To The Parent Company GR 3Y
-36.68% 62.440% -38.62% 56.071% -27.79% 87.570% -5.78% 90.357%
Total Assets GR 3Y
22.28% 64.323% -- -- -7.27% 61.060% -- --
Share Equity Without Minority Interest GR 3Y
-9.15% 75.158% -- -- 17.28% 85.819% -- --
Equity GR 3Y
-11.4% 72.820% -- -- 9.97% 85.940% -- --
Total Liabilities GR 3Y
3652.26% 42.459% -- -- -69.12% 10.798% -- --
Basic Earning Per Share GR 3Y
-501.71% -15.028% -9175.04% -18.283% -116.06% -2.048% 24.16% -0.602%
Net Assets Per Share GR 3Y
-79.03% -8.462% -- -- 68.83% -3.026% -- --
Other Indicators
Currency Unit
HKDHKDHKDHKD

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Stone Pharmaceutical Group Co., Ltd. is an investment holding company mainly engaged in drug production and sales. The company sells its products under the brand name "Stone Medicine". The company includes four business divisions: proprietary medicine, antibiotics (intermediates and API), vitamin C (API) and caffeine and other (API), respectively engaged in the production and sales of related drugs. The company's proprietary medicines include antibiotics, cardio-cerebrovascular drugs, diabetes drugs, psychiatric drugs, antineoplastic drugs and traditional Chinese medicine products. Through its subsidiaries, the company is also engaged in providing drug research and development services and sewage and drug by-product treatment business.
CEO: Dongchen Cai
Market: Hong Kong motherboard
Futu Hot List
HKUSCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top